Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Some medications act on GLP-1 receptors only
WAYS TO SUPPORT MY WORK Massive compound shakeup00:00:43 Why compound users need this00:01:25 Sponsor, Shed obesity care00:02:11 Breaking news changed everything00:02:28 OTP semaglutide exclusive00:03:28 DDC list explained00:04:24 Novos lab findings00:09:57 302% dose shocker00:13:03 Catalents contamination mess00:16:33 Lillys B12 tirzepatide bombshell00:19:34 Is the molecule changing?00:21:46 New oral GLP-1 contender Cheap Zepbound Incoming for Medicare, But CMS Just Issued a Catch On this episode of the podcast, host Dave Knapp breaks down the latest updates on potential GLP-1 receptor agonists coverage for people on Medicare living with obesity
Novo Nordisk said patent expiry was a natural part of the pharmaceutical product lifestyle and the company was exploring new molecules, combinations and formulations of treatments, both organically and through external opportunities
Ann Intern Med 2001;134:370e9
